Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Therapeutics, Inc. on November 29, 2022. The report discloses a material event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On November 29, 2022, Susan Kalled, PhD, departed her position as Chief Scientific Officer of the Company. This departure triggers specific compensatory arrangements outlined in her employment agreement dated April 26, 2021.
Guidance, Outlook, and Management Commentary
The filing does not provide updated financial guidance, strategic outlook, or general management commentary. The primary disclosure concerns the terms of Dr. Kalled's separation, which include:
- Severance equal to twelve months of base salary, payable in substantially equal installments over twelve months.
- Reimbursement of COBRA premiums for health benefit coverage or eligibility to participate in the group employee benefits plan for up to twelve months.
- These benefits are subject to the execution of a separation agreement and release and the absence of breaches of continuing obligations.
Investor Verification Checklist
- Verify the execution of the separation agreement and release required for Dr. Kalled to receive severance and benefits.
- Confirm the timeline for the twelve-month installment payments of the base salary severance.
- Assess the potential impact of the Chief Scientific Officer's departure on ongoing clinical trials and research pipelines.
- Review subsequent filings for the appointment of a replacement Chief Scientific Officer.